Komentarai Siųsti draugui Spausdinti Vertinimas Neįvertintas

GRD: JSC “Grindeks” the audited profit in 2008 - 9 million lats

Spekuliantai.lt | 2009-04-27 | NASDAQ OMX biržų naujienos | perskaitė: 1294
Raktiniai žodžiai: Grindeks, GRD
GRD: JSC “Grindeks” the audited profit in 2008 - 9 million lats

Grindeks Annual report/ annual accounts 27.04.2009

JSC “Grindeks” the audited profit in 2008 - 9 million lats

The audited financial results confirm that “Grindeks” has worked successfully
last year; the net profit in 2008 has reached 9 million lats, exceeding the
result of 2007 by 1.9 million lats or 26,8%. Turnover of the Group has reached
62.1 million lats in 2008, which is by 10.6 million lats or by 20.6% more than
in 2007.

Chairman of the Board of “Grindeks” Janis Romanovskis: “The results of 2008
confirm that our business strategy and the set priorities have been accurate
because the Group has operated successfully last year. It is known to everybody
that the last year will be marked as the beginning of the global financial and
economic crisis in the world history, therefore achievement of the strategic
goal which envisages keeping growth rates and ensuring the previous increase in
turnover and profit was a special task for the company. Development of
“Grindeks” is characterized by another important achievement; regardless of the
external financial and economic conditions, in 2008, the Group purposefully
continued to implement the investment programm and in January 2009, the new
final dosage forms plant was opened by investing a total of 9.1 million lats.”

JSC „Grindeks” forecasts - if current growth dynamics will sustain in
substancial markets, then the year 2009 will end successfully with 10 - 30 %
profit growth.
In 2009 „Grindeks” continues reasearch of new combinations of the existing
original products. At the end of this year or begining of next year
registration process of the new medication will be started.


“Grindeks” is the leading pharmaceutical company in the Baltic states. Its
main fields of action are: research, development, manufacturing and sale of
original products, generics and active pharmaceutical ingredients. “Grindeks”
specializes in the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups. “Grindeks” Group consists of four subsidiary companies in
Latvia, Estonia and Russia, as well representatives and representative offices
in fourteen countries. Products of the company are exported to more than 40
countries and its export comprises more than 96% of the total turnover. The
main markets are: the Baltic States, Russia and other CIS countries, Japan,
USA. JSC “Grindeks” shares are listed in the Official List of “NASDAQ OMX
Riga”.


Further information:

Laila Kļaviņa
Head of the Communications Department
JSC “Grindeks”
e-mail: laila.klavina@ grindeks.lv
Phones. 67083370, 29256012



1. grindeks_annual_report_2008_en_eur.pdf
(https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=222848)
2. grindeks_audited_annual_report_2008_lvl.pdf
(https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=222849)

Taip pat skaitykite

DPK: Decisions of the regular meeting of shareholders dated 27.05.2013

VLN: NEW MUTUAL FUND TO THE BALTIC FUND CENTER

VLN: The results of the primary placement auction of Lithuanian Government securities

VLN: VVP pirminio platinimo aukciono rezultatai

2013-05-27 | NASDAQ OMX biržų naujienos 2013-05-27 | NASDAQ OMX biržų naujienos 2013-05-27 | NASDAQ OMX biržų naujienos 2013-05-27 | NASDAQ OMX biržų naujienos

Komentarai



Ekonominis kalendorius

Prekybos statistika realiu laiku

Techninės analizės įrankis

Privatumo politika Reklama Kontaktai Paskolos RSS RSS
© 2006-2021 UAB All Media Digital